About Us (cont.)

The company’s lead compound, Rx100, is being developed initially as a drug to prevent death and rescue life as a result of the unintended exposure to lethal ionizing radiation – including GI-ARS and HEM-ARS.

RxBio also has data showing efficacy of Rx100 in models of cholera- and toxin-induced secretory diarrhea and NSAID-induced stomach erosions (e.g., aspirin, ibuprofen, etc.). In addition, the company has an impressive line-up of follow-on compounds (Rx200 and 300 series) suitable for indications in addition to ARS.

To date, the bulk of the company’s funding has derived from nondilutive, third-party sources – including funding from one or more agencies of the National Institutes of Health (NIH) – i.e. the National Institute of Allergy and Infectious Disease (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the U.S. Army / Department of Defense.

RxBio has successfully completed commercial-scale production of Rx100 and is near completion of non-clinical toxicology studies in preparation of clinical studies. The company has been successful in developing ARS animal models, including GI-ARS animal models, predictive of humans and has successfully demonstrated a significant rescue and survival benefit when Rx100 is administered up to 24 hours after exposure to lethal ionizing radiation in that model.